by guest www.bloodjournal.org From 2 Case #1. A 48-year-old male is admitted to the intensive care unit (ICU) with worsening multi-organ system failure due to bacteremia from an abdominal wound. His platelet count was 160x10 9 /L 5 days ago, and today he has severe thrombocytopenia, (platelet count = 33x10 9 /L). He has mild anemia (hemoglobin 115 g/L), normal prothrombin time (34 seconds), international normalized ratio (1.1) and fibrinogen (2.0 g/L). There are no overt signs of bleeding. You contemplate whether to administer a platelet transfusion. Case #2. A 12-day-old female infant born at 29 weeks gestational age becomes irritable, stops tolerating enteral feeds, has increased apnea and requires reventilation. Abdominal x-ray and head ultrasound are normal. Broad-spectrum antibiotics are started. A blood culture grows gram-negative bacilli within 24 hours of culture. She develops severe thrombocytopenia (platelet count = 33x10 9 /L). You contemplate whether to administer a platelet transfusion. We thank Deborah Cook, Maureen Meade, Francois Lauzier, Karen Choong and Paul Clarke for reviewing the manuscript and the recommendations. We thank Mrs. Elizabeth Uleryk for her help performing the literature search.
Introduction
Thrombocytopenia is common among critically ill patients. In a recent systematic review, thrombocytopenia (defined as a platelet count below 150x10 9 /L) was present in 8.3%-67.6% of adult patients on admission to the intensive care unit (ICU) and acquired by 13%-44% of patients during their ICU stay. 1 Thrombocytopenia in ICU patients is an independent predictor of mortality in adults; 1 is associated with bleeding; 2 and often deters practitioners from performing invasive procedures, which are frequently required in this setting.
Thrombocytopenia also complicates critical illness in younger age groups: 20%-50% of critically ill neonates develop thrombocytopenia, including 5%-10% with platelet counts less than 50x10 9 /L. 3 In contrast to patients with chemotherapyinduced thrombocytopenia, ICU-associated thrombocytopenia is multifactorial and develops as a result of infection, inflammation and coagulation factor consumption. Platelet turnover is often increased in critical illness, which may pose less of a hemostatic risk than patients with bone marrow failure; conversely, complex comorbidities may add to the overall risk of bleeding. The principal treatment for ICU-associated thrombocytopenia is to treat the underlying cause.
Platelet transfusions are often used to treat thrombocytopenia in the ICU 4 despite the lack of high quality published evidence suggesting benefit. Local clinical guidelines and recommendations regarding platelet transfusion thresholds for critically ill patients vary and are based largely on expert opinion. The benefits of platelet transfusions on clinical outcomes such as bleeding avoidance and survival are uncertain. The objectives of this focused review were to systematically review the literature on the effect of platelet transfusions on platelet count increment, bleeding, and mortality and to formulate recommendations for or against the use of platelet transfusions for non-bleeding critically ill neonates, children, and adults with severe (platelet count <50x10 9 /L) 1 thrombocytopenia.
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Methods
Our research team was composed of transfusion medicine specialists including one adult hematologist, three pediatric hematologists and two methodologists.
Investigators had experience in platelet transfusion studies and research in ICUassociated thrombocytopenia. We also elicited feedback from three adult, one pediatric and one neonatal ICU physician, all with experience in research methodology.
Search strategy and study selection
We searched Medline and Embase for relevant articles published until November 2012 using the keywords "critical illness", "thrombocytopenia" and "platelet transfusions" (supplemental Appendix A). We manually searched reference lists of primary articles and relevant reviews and solicited additional articles from authors. Studies were eligible if the study population was critically ill patients of any age who had thrombocytopenia and who received platelet transfusions and at least one of the following was reported as a study outcome: platelet count increment, bleeding, or mortality. We included all experimental and observational study designs. We excluded studies of specific thrombocytopenic syndromes such as drug-induced immune thrombocytopenia, primary immune thrombocytopenia, or neonatal alloimmune thrombocytopenia; cardiac ICUs only; fewer than 10 patients; review articles; redundant publications; abstract-only publications; and non-English language articles. One author screened titles for For personal use only. on October 28, 2017. by guest www.bloodjournal.org From relevance and a second author assessed abstract and full texts for eligibility. Six reviewers independently performed the data abstraction.
Quality assessments
The methodological quality of individual studies was evaluated using criteria established for the reporting of randomized and non-randomized studies. 5, 6 Each article was assessed independently by all six investigators then discussed as a team. During the discussion, we refined the quality assessment criteria to suit the topic by adding a criterion (adjustment of confounding) and providing explicit definitions of appropriateness of patient selection, outcome, exposure, and follow-up pertinent to platelet transfusion studies. For RCTs, the adequacy of randomization, allocation concealment, blinding, follow-up, outcome assessment, and analysis were assessed. 5 We added applicability to our assessment of overall study quality to gauge the extent to which the study addressed our research question. Methodological quality of all studies was re-examined in pairs and determined by consensus (supplemental Appendix B).
GRADE Recommendations
Our intent was to formulate recommendations for or against the use of platelet transfusions using Grading of Recommendations Assessment, Development, and Evaluation (GRADE) which incorporates the quality of the evidence, benefits and risks, and resource utilization. 7 or low quality of evidence, respectively. Once our systematic review was complete, it became evident that there was insufficient evidence upon which to base evidence-based recommendations for or against platelet transfusions in this setting. Our conclusions were reached by consensus.
Results
Our initial literature search yielded 1,471 citations, of which 1,361 were excluded after screening titles. An additional 47 articles were excluded after abstract review and 45 were excluded after full text review. Three articles were added after reviewing reference lists and authors' suggestions. Finally, 21 studies in neonates (n=15), adults (n=5) and children (n=1) were included. Only five studies directly addressed the research question; the other 16 were indirectly applicable, and often considered platelet transfusions as an outcome, rather than the intervention. Our search identified only one RCT in neonates. 8 
Critically ill adults

Platelet count increment
Five observational studies addressed the effect of platelet transfusions on platelet count increment in critically ill adults (Table 1) . 4, [9] [10] [11] [12] In two studies, one platelet transfusion resulted in a median increase in the platelet count of 15x10 9 /L although results varied considerably across patients. 4, 9 Sustained For personal use only. on October 28, 2017. by guest www.bloodjournal.org From correction of thrombocytopenia to a platelet count above 100x10 9 /L was rarely achieved with platelet transfusions.
Bleeding
No study reported the impact of platelet transfusions on bleeding avoidance in critically ill adults.
Mortality
Three studies addressed the relationship between platelet transfusions and mortality ( Table 2) . [10] [11] [12] The use of platelet transfusions was not associated with improved survival; however, data were derived from observational studies of low methodological quality. Some studies 11, 13 reported an association between platelet count recovery (by transfusion or otherwise) and survival.
Data synthesis
Only one observational study of moderate quality addressed the impact of platelet transfusions on platelet count increment in critically ill adults. 9 The other four studies indirectly addressed our research question. 4, [10] [11] [12] There was insufficient evidence to suggest a clinical benefit of platelet transfusions for patients with severe thrombocytopenia, and post-transfusion platelet count increments were modest.
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Critically ill preterm neonates
Platelet count increment
Platelet counts increased by 50 -95 x10 9 /L after a platelet transfusion in three studies ( Table 1) . Platelet doses and number of transfusions were not consistently reported. 8, 14, 15 Bleeding Nine studies reported the effect of platelet transfusions on bleeding in neonates (Table 3) . 8, 14, [16] [17] [18] [19] [20] [21] [22] One study reported a 21% reduction (95% confidence interval, 8%-31%) in minor bleeds in the 12 hour period after platelet transfusion compared with the 12 hour period before transfusion. 22 One RCT in preterm infants of <1500 grams birthweight who were randomized within 72 hours of birth reported no difference in incidence or extension of intraventricular hemorrhage using platelet transfusion thresholds of 50x10 9 /L or 150x10 9 /L. 8 Unadjusted analyses from four observational studies reported a higher incidence of bleeding events with additional platelet transfusions. 14, 16, 18, 20 Mortality Twelve studies examined the association between platelet transfusions and mortality in neonates ( Table 2 ). In unadjusted analyses, the risk of death was highest among neonates who received the most platelet transfusions 8, 14, [16] [17] [18] [19] 21, [23] [24] [25] [26] [27] . In the only RCT, there was no difference in mortality with a platelet transfusion trigger of 50x10 9 /L or 150x10 9 /L. 8 
Data synthesis
Of the 15 neonatal studies, four were directly applicable to our research question; however, study quality was graded as low. The findings from one RCT showed no difference in intraventricular hemorrhage with a platelet transfusion threshold of 50x10 9 /L or 150x10 9 /L in preterm neonates immediately after birth; however, a description of the randomization procedure was not provided, allocation concealment was uncertain, bleeding assessments were not validated and infants who developed thrombocytopenia after 72 hours were not included. Other studies in neonates could not exclude the possibility of harm with platelet transfusions 8 .
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Critically ill children
We identified one prospective cohort study of critically ill children (n= 138), which reported no difference in mortality between transfused and non-transfused children in adjusted analyses 28 .
Recommendation: For critically ill children with severe thrombocytopenia and no evidence of bleeding, there is insufficient evidence to recommend for or against platelet transfusion.
Discussion
The key finding from this focused review is the lack of evidence underpinning a very common medical intervention in critically ill patients with thrombocytopenia.
High quality data to support or refute the need for prophylactic platelet transfusion in the ICU are lacking despite the fact that this intervention is commonly used. There is a pressing need for research on the efficacy and safety of this intervention.
Our intention was to synthesize the literature and provide recommendations for or against the use of platelet transfusions using GRADE methodology; however the data were too weak to support evidence-based recommendation in this regard. In fact, there were no RCTs addressing platelet count thresholds in critically ill adults or children, and the only RCT in neonates was published 20 years ago and evaluated platelet transfusion thresholds that may not be as relevant to current practice. Thus, we felt it was more prudent to avoid recommendations altogether, which would essentially reflect opinion and may undermine the design of future randomized trials.
Platelet transfusions are commonly used in the ICU; 9-30% of critically ill patients receive a transfusion, approximately 59-68% of which are used to prevent, rather than to treat bleeding. 9, 29, 30 Despite the high utilization of platelet products, platelet transfusion practices in the ICU are variable. 31, 32 The use of platelet transfusions in patients with sepsis was addressed in the 2012 Surviving Sepsis Campaign 33 . This guideline recommended platelet transfusions for adults with platelet counts <20x10 9 /L who were considered to be at significant risk of bleeding. This was a weak recommendation reflecting consensus opinion and informed by data derived from other patient groups. Similar weak recommendations for platelet transfusions were made for pediatric patients. For neonates, most published guidelines, which are also largely opinion-based, have recommended platelet transfusion thresholds between 20 and 50x10 9 /L for stable neonates and 30-100x10 9 /L for preterm infants. 21, 34, 35 For personal use only. on October 28, 2017. by guest www.bloodjournal.org From Although thrombocytopenia has been independently linked to death in the ICU 1 , the association between low platelet counts and poor clinical outcomes does not establish causality, nor does it provide adequate evidence to support correcting the thrombocytopenia with platelet transfusions. These studies are subject to confounding by indication since patients who receive multiple platelet transfusions are often more severely ill. A platelet count below 30x10 9 /L is commonly used to define very severe thrombocytopenia in critical illness; 13 however, the use of a specific platelet count threshold may incorrectly convey that there are step-wise changes in bleeding risk or other outcomes. Critically ill patients are heterogeneous with respect to admission diagnoses, co-morbidities, medications, dynamic changes in coagulation parameters and the need for invasive procedures, which may individually or cumulatively influence the risk of bleeding. Current data do not yet allow for the stratification of bleeding risk, which may be more informative than platelet count alone.
For the non-bleeding critically ill patients with platelet counts below 10 -20x10 9 /L 33 prophylactic platelet transfusions may be reasonable. This suggestion is supported by data from randomized trials in patients with chemotherapyassociated thrombocytopenia, which showed that serious bleeding could be reduced with platelet transfusions when the platelet count is below 10x10 9 /L. 30, 36 However these data may not be generalizable to critically ill patients who have frequent comorbidities and commonly require invasive procedures which add to For personal use only. on October 28, 2017. by guest www.bloodjournal.org From the overall bleeding risk. In addition to platelet count, the decision to transfuse platelets will depend on age, weight, other hemostatic parameters and the need for invasive procedures.
Strengths of this review were the methodology used to identify studies and assess study quality, and our conservative approach used to formulate conclusions. Our team is experienced in guideline development and transfusion medicine research and our conclusions were informed by feedback from broad range of critical care specialists. Limitations were the inability to make specific recommendations for or against platelet transfusions in critically ill patients given the lack of data. Median increase after single PLT transfusion was 14x10 9 /L (IQR, -2 -30x10 9 /L).
Moderate
Stephan 1999 11 147 Adults; surgical ICU Prospective cohort PLT count rose above 40-50x10 9 /L (but never above 100x10 9 /L) after transfusion.
Low
Stephan 1999 59% of transfusions increased counts >40x10 9 /L; 8% of transfusions increased counts <20x10 9 /L; median platelet count increase from 27x10 9 /L (IQR, 19-36x10 9 /L) to 79x10 9 /L (IQR, 47-126x10 9 /L).
Moderate
Andrew 1993 
